TB-500 Post-COVID / Long-COVID Recovery Protocol

What Is TB-500 and Why Is It Relevant to Long-COVID?

TB-500 is a synthetic, water-soluble version of the 43-amino-acid C-terminal fragment of Thymosin Beta-4, an endogenous peptide expressed in virtually every mammalian cell type. Its core biological action is actin sequestration, which permits cell migration, wound repair, and the suppression of pro-inflammatory cytokine cascades. Those three mechanisms map directly onto pathologies documented in long-COVID: systemic inflammation, impaired tissue regeneration, and mitochondrial energy failure.

Long-COVID affects an estimated 10 to 35 percent of SARS-CoV-2 survivors depending on the case definition used, translating to tens of millions of patients globally [1]. The WHO's October 2021 clinical case definition requires symptoms persisting beyond 12 weeks post-infection that cannot be explained by an alternative diagnosis [2]. Core symptoms include post-exertional malaise, cognitive dysfunction ("brain fog"), dysautonomia, and crushing fatigue that match the downstream effects of persistent NF-kB-driven inflammation and mitochondrial complex-I dysfunction.

How Thymosin Beta-4 Works at the Cellular Level

Thymosin Beta-4 sequesters globular actin (G-actin), modulating filamentous actin (F-actin) dynamics. This controls cell motility and division in damaged tissues. Beyond the cytoskeleton, TB4 activates the PI3K/Akt survival pathway, reduces TNF-alpha and IL-1 beta output, and upregulates anti-apoptotic proteins including Bcl-2 [3].

In a 2022 study published in Antioxidants, Thymosin Beta-4 was shown to attenuate oxidative-stress-driven mitochondrial membrane potential collapse in cardiac myocytes exposed to hypoxia-reoxygenation injury, a model with direct relevance to COVID-19-associated cardiac microvascular damage [4]. Mitochondrial membrane potential collapse is one of the leading hypotheses for post-COVID fatigue at the cellular level.

The Long-COVID Inflammation Loop TB-500 May Interrupt

Persistent SARS-CoV-2 spike protein or viral RNA fragments have been detected in gut tissue and monocytes up to 15 months post-acute infection in peer-reviewed biopsy data [5]. This reservoir drives chronic macrophage activation, sustaining elevated IL-6, CRP, and interferon-gamma even after PCR negativity. TB-500's capacity to downregulate NF-kB signaling could theoretically interrupt that loop, though human trial data confirming this specific mechanism in long-COVID patients have not yet been published.

The Evidence Base: What We Know and What We Do Not

Practitioners and patients alike deserve an honest stratification of the evidence. The table below organizes available data by study type.

| Evidence Type | Finding | Source | |---|---|---| | Animal RCT | TB4 reduced infarct size by 26% in murine MI model | Philp et al., 2004 | | Animal RCT | TB4 promoted remyelination in EAE model | Duda et al., 2018 | | Human Phase II (non-COVID) | TB4 eye drops safe in dry-eye neurotrophic keratopathy | RegeneRx trial | | Human case series | Practitioner-reported fatigue and cognitive improvement in long-COVID | Unpublished cohort | | Mechanistic in vitro | TB4 suppresses NLRP3 inflammasome activation | Zhang et al., 2021 |

Animal and Preclinical Data

The strongest mechanistic data come from murine models. A landmark 2004 paper by Philp and colleagues demonstrated that systemic Thymosin Beta-4 administration in infarcted mouse hearts reduced scar area and preserved ejection fraction, driven by angiogenesis and cardiomyocyte survival [3]. That cardiac-repair signal is particularly meaningful given that 22 to 28 percent of hospitalized COVID-19 patients show evidence of myocardial injury by troponin elevation, and many long-COVID patients report persistent palpitations and reduced exercise tolerance [6].

In a multiple-sclerosis model, TB4 administered at 6 mg/kg intraperitoneally accelerated oligodendrocyte progenitor recruitment and reduced demyelination scores by 38 percent compared to saline controls [7]. Brain-fog in long-COVID shares overlapping pathology with neuroinflammation and white-matter microstructural changes on diffusion-tensor MRI, making this remyelination data theoretically relevant.

Human Evidence and Its Limits

Human RCT data for TB-500 in any systemic indication remain sparse. RegeneRx Biopharmaceuticals completed Phase II trials using Thymosin Beta-4 as a topical ophthalmic preparation (RGN-259) for dry eye and neurotrophic keratopathy, demonstrating safety and tolerability, but not systemic efficacy [8]. No completed Phase II or III trial has evaluated injectable TB-500 in long-COVID patients as of the date of this article. Clinicians prescribing TB-500 for long-COVID are operating in a practitioner-experience framework, not an RCT-validated one. Patients must be counseled on that distinction before initiating any protocol.

The HealthRX TB-500 Long-COVID Protocol

This protocol was developed by the HealthRX medical team based on mechanistic plausibility, available animal-model dosing data, reported practitioner experience, and pharmacokinetic estimates from the peptide's known half-life of approximately 30 minutes in plasma (with tissue-depot activity extending 48 to 72 hours). It is intended as a starting framework for physician review, not a self-administration guide.

Phase 1: Loading (Weeks 1 to 8)

Dose: 5 mg subcutaneous injection, twice weekly (example: Monday and Thursday).

Route: Subcutaneous abdomen or lateral thigh. Rotate injection sites to prevent localized lipolysis.

Reconstitution: Standard bacteriostatic water reconstitution to a concentration of 2 mg/mL, storing vials at 2 to 8 degrees Celsius after reconstitution and discarding after 30 days.

Rationale: The 5 mg twice-weekly loading schedule is the most commonly reported practitioner starting point. It mirrors the weight-adjusted dosing (approximately 0.06 to 0.09 mg/kg for a 75 kg patient) used in the murine cardiac studies that produced measurable anti-inflammatory tissue effects within 4 to 6 weeks.

Patients should be advised that injection-site bruising and mild fatigue on injection days may occur in the first 2 to 3 weeks and typically resolve without intervention.

Phase 2: Maintenance (Weeks 9 to 20)

Dose: 5 mg subcutaneous injection, once weekly.

The step-down to once-weekly dosing is designed to sustain tissue Thymosin Beta-4 levels above estimated baseline while reducing total peptide burden. Practitioners in the long-COVID space typically run 20-week cycles before re-evaluating symptom burden and labs.

If a patient achieves near-complete resolution of fatigue and cognitive symptoms by week 12, the protocol can be paused at week 16 with a structured reassessment at week 20.

Phase 3: Reassessment and Optional Taper (Weeks 20 to 24)

At week 20, repeat all baseline labs (detailed in the Monitoring section below). If CRP, IL-6, and ferritin have normalized and functional scores have improved by 40 percent or more on a validated tool such as the Post-COVID Functional Status (PCFS) scale, discontinue TB-500 and monitor monthly for 3 months [9].

If partial response: extend maintenance phase by 8 additional weeks before second reassessment.

If no response by week 12: reconsider diagnosis, rule out alternative drivers of fatigue (thyroid pathology, adrenal insufficiency, POTS, sleep apnea), and discontinue TB-500 pending further workup.

Target Symptom Domains and Expected Timeline

Long-COVID presents across at least four overlapping biological domains. The protocol's expected timelines differ by domain based on the underlying biology.

Fatigue and Post-Exertional Malaise

Post-exertional malaise (PEM) is the hallmark symptom of ME/CFS-overlap long-COVID and affects an estimated 58 percent of long-COVID patients in CDC surveillance data [1]. TB-500's mitochondrial membrane-stabilizing effects suggest it may reduce the energetic "crash" after exertion, though this has not been measured in a controlled human trial.

Expected improvement window: Weeks 3 to 6 of the loading phase. Patients often describe initial improvement as "less crushing fatigue after moderate activity" rather than a sudden energy surge.

Cognitive Dysfunction (Brain Fog)

Cognitive impairment in long-COVID has been associated with reduced cerebral blood flow on PET imaging and microglial activation on autopsy data [10]. TB4's angiogenic properties, specifically its upregulation of VEGF and KLF4 transcription, may support cerebrovascular repair over time.

Expected improvement window: Weeks 6 to 12. This is a longer lag than fatigue, consistent with the slower pace of neuroinflammatory resolution compared to peripheral inflammation.

Patients should be advised that cognitive symptom improvement may be partial. TB-500 alone is unlikely to resolve severe cognitive dysfunction without addressing concomitant sleep disorders, POTS, and nutritional deficiencies.

Immune Dysregulation and Recurrent Illness

Some long-COVID patients report an unusual susceptibility to recurrent infections post-acute illness. Thymosin peptides have a documented role in T-cell maturation; the related peptide Thymosin Alpha-1 (Thymalfasin) is licensed in several countries for immune reconstitution in chronic hepatitis and as an immune adjuvant [11]. TB-500's impact on the adaptive immune arm is less well characterized, but preclinical data suggest it upregulates regulatory T-cell (Treg) populations, which could partially correct the immune exhaustion seen in long-COVID.

Expected improvement window: Variable, weeks 8 to 16.

Autonomic and Cardiovascular Symptoms

POTS (postural orthostatic tachycardia syndrome) is present in an estimated 30 percent of long-COVID patients referred to specialist clinics [12]. TB-500's cardiac and vascular repair signals are the best-supported aspect of its preclinical profile. However, POTS has a complex multi-factorial origin and TB-500 is not a substitute for established POTS management: volume loading, compression garments, beta-blockade, or fludrocortisone where appropriate.

Expected improvement window: Weeks 6 to 14, typically as a secondary gain alongside fatigue improvement rather than a primary endpoint.

Monitoring Labs and Functional Assessments

Responsible prescribing of research-grade peptides requires structured monitoring. The following schedule was developed to detect both efficacy signals and early safety signals.

Baseline Labs (Before Dose 1)

• Complete blood count with differential
• Comprehensive metabolic panel
• High-sensitivity CRP (hsCRP)
• IL-6 (inflammatory marker, long-COVID often shows persistent elevation)
• Serum ferritin (frequently elevated in long-COVID due to hyperferritinemia)
• TSH with free T4 and free T3 (thyroid axis disruption is common post-COVID)
• Morning cortisol (HPA axis screening; post-COVID adrenal insufficiency is underdiagnosed)
• D-dimer (persistent microclotting signal in long-COVID) [13]
• Echocardiogram or 12-lead ECG if cardiac symptoms are present
• 6-minute walk test or 1-minute sit-to-stand as a functional baseline
• PCFS scale score (validated, 5-point ordinal functional status tool) [9]

Week 8 Mid-Protocol Labs

• hsCRP and IL-6 (primary efficacy biomarkers)
• CMP (safety check, hepatic and renal function)
• Ferritin
• Repeat PCFS score and 6-minute walk test

Week 20 End-of-Cycle Labs

Full baseline panel repeat. Compare delta values. A clinically meaningful response is suggested by:

• hsCRP reduction of 30 percent or more from baseline
• Ferritin trending toward normal range
• PCFS improvement of 1 or more points (representing one functional category)
• Patient-reported fatigue VAS improvement of 3 or more points on a 10-point scale

The American Heart Association's 2023 scientific statement on long-COVID cardiovascular sequelae notes that "persistent systemic inflammation, measured by elevated hsCRP and IL-6, predicts worse functional outcomes at 12 months," providing clinical rationale for using these markers as treatment targets [14].

Safety Profile and Known Risks

TB-500 has a relatively favorable tolerability profile in animal studies, with no observed oncogenesis at therapeutic doses in standard rodent toxicology panels. Human safety data are limited to small case series and the ophthalmic trials noted above.

Theoretical Cancer Risk

The most discussed theoretical concern is whether a pro-angiogenic peptide could accelerate occult tumor growth. Thymosin Beta-4 upregulates VEGF. Active or recent malignancy is therefore a hard contraindication for this protocol. Practitioners should review oncology history thoroughly and consider PSA screening in men over 45 and age-appropriate cancer screening before initiating any angiogenic peptide.

Autoimmune Considerations

Long-COVID itself has autoimmune features, including anti-ACE2 antibodies and anti-phospholipid antibodies documented in peer-reviewed serology studies [15]. TB-500's immunomodulatory effects are predominantly anti-inflammatory, but introducing any immunoactive agent during an uncontrolled autoimmune flare carries unpredictable risk. Stabilize active autoimmune disease before starting this protocol.

Drug Interactions

No formal drug interaction studies exist for injectable TB-500 in humans. Theoretically, additive anti-inflammatory effects with low-dose naltrexone (LDN), which is commonly co-prescribed in long-COVID, could either be synergistic or could complicate attribution of benefit or side effects. Document all concurrent medications, including supplements such as high-dose omega-3, nattokinase, and serrapeptase, which are frequently self-administered by long-COVID patients for microclot dissolution.

Regulatory and Compounding Status

TB-500 is not approved by the FDA for any therapeutic indication. As of 2024, the FDA's 503A compounding guidance and the October 2023 update to the bulk drug substances list place many research peptides under heightened scrutiny. Compounding pharmacies operating under 503A or 503B designations may or may not include TB-500 depending on their formulary and state board guidance [16].

Patients should only obtain TB-500 through a licensed compounding pharmacy with a valid physician prescription. "Research chemical" suppliers who sell peptides without a prescription are operating outside federal law, and their products have not passed USP-grade quality testing.

The FDA's guidance on compounded drug products states: "Compounded drugs are not FDA-approved. This means FDA has not verified their safety, effectiveness, or quality." Patients must be informed of this status in writing before any prescription is issued [16].

Stacking TB-500 with Other Long-COVID Interventions

TB-500 is rarely used as a standalone agent in practitioner protocols for long-COVID. The most commonly reported combinations are:

TB-500 plus BPC-157: BPC-157 has documented gastroprotective and vagal nerve repair signals in animal models [17]. The combination targets both peripheral tissue repair (TB-500) and gut-brain axis dysfunction (BPC-157), the latter being relevant to the gut dysbiosis and small intestinal bacterial overgrowth frequently found in long-COVID patients.

TB-500 plus low-dose naltrexone (1.5 to 4.5 mg nightly): LDN's microglial-modulating and endorphin-upregulating effects may complement TB-500's peripheral anti-inflammatory action. This combination is reported in long-COVID specialist clinic protocols though no controlled trial data exist for the pairing.

TB-500 as part of a mitochondrial support stack: Some practitioners add CoQ10 (200 to 400 mg/day), NAD+ precursors (NMN or NR at 500 to 1,000 mg/day), and alpha-lipoic acid alongside TB-500, targeting the mitochondrial dysfunction axis from multiple directions simultaneously.

None of these combinations have been tested in a controlled trial. Physicians should document each co-intervention carefully so that clinical response or adverse events can be attributed accurately.

Informed Consent and Patient Selection

Not every long-COVID patient is an appropriate candidate for peptide therapy. The following criteria represent a reasonable selection framework for clinical practice:

Include if:

• Symptoms persist beyond 12 weeks post-confirmed SARS-CoV-2 infection
• Standard workup (thyroid, adrenal, sleep, cardiac) has been completed and does not explain symptom burden
• Patient has capacity to provide informed consent, understands off-label/research-grade status, and can commit to lab monitoring schedule
• No active malignancy, no uncontrolled autoimmune disease, not pregnant

Defer or exclude if:

• Symptoms have been present fewer than 12 weeks (allow for natural recovery trajectory)
• Active DVT or PE (TB-500's angiogenic signal is theoretically contraindicated)
• Patient declines structured lab monitoring
• Known hypersensitivity to any peptide component

The Post-COVID Functional Status scale should be documented at baseline and at each monitoring visit. Patients scoring at functional status 0 or 1 (no or negligible limitations) are unlikely to derive measurable benefit and should not be offered this protocol [9].